A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Clinical trial NCT04103892 · COMPLETED
Trial details
- NCT number
- NCT04103892
- Sponsor
- Clexio Biosciences Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-05
- Primary completion
- 2022-09-21
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.